Abstract：
D-allulose, D-sorbose and D-tagatose are D-fructose isomers that are called rare sugars. These rare sugars have been studied intensively in terms of biological production and food application as well as physiological effects. There are limited papers with regard to the transporters mediating the intestinal absorption of these rare sugars. We examined whether these rare sugars are absorbed via sodium-dependent glucose cotransporter 1 (SGLT1) as well as via GLUT type 5 (GLUT5) using rats. High-fructose diet fed rats, which express more intestinal GLUT5, exhibited significantly higher peripheral concentrations, Cmax and AUC0–180 min when D-allulose, D-sorbose and D-tagatose were orally administrated. KGA-2727, a selective SGLT1 inhibitor, did not affect the peripheral and portal vein concentrations and pharmacokinetic parameters of these rare sugars. The results suggest that D-allulose, D-sorbose and D-tagatose are likely transported via GLUT5 but not SGLT1 in rat small intestine.
摘要：
D-阿洛酮糖,D-山梨糖和D-塔格糖是D-果糖异构体，被称为稀有糖。这些稀有糖已经在生物生产和食品应用以及生理效应方面进行了深入研究。关于介导这些稀有糖的肠吸收的转运蛋白的论文有限。我们使用大鼠检查了这些稀有糖是否通过钠依赖性葡萄糖协同转运蛋白1（SGLT1）以及通过GLUT5型（GLUT5）吸收。高果糖饮食喂养大鼠，表达更多的肠道GLUT5，表现出明显更高的外周浓度，当D-阿洛酮糖时，Cmax和AUC0-180min，口服D-山梨糖和D-塔格糖。KGA-2727，一种选择性SGLT1抑制剂，不影响这些稀有糖的外周和门静脉浓度和药代动力学参数。结果表明，D-阿洛酮糖，D-山梨糖和D-塔格糖可能通过GLUT5而不是SGLT1在大鼠小肠中运输。
